189.168.236.69 (talk) |
Updating {{drugbox}} - verified and watched fields unchanged - +verified revid - updated 'CASNo_Ref' per Chem/Drugbox validation (report errors or [[us |
||
| Line 1: | Line 1: | ||
{{Drugbox| |
{{Drugbox| verifiedrevid = 306701498 |
||
| |
|||
|IUPAC_name = 2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1''H''-benzo[''d'']imidazole |
|IUPAC_name = 2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1''H''-benzo[''d'']imidazole |
||
| image=Lansoprazole.svg |
| image=Lansoprazole.svg |
||
| image2 = Lansoprazole 3D.png |
| image2 = Lansoprazole 3D.png |
||
| width = 250px |
| width = 250px |
||
| CASNo_Ref = {{cascite}} |
|||
| CAS_number=103577-45-3 |
| CAS_number=103577-45-3 |
||
| ChemSpiderID = 3746 |
| ChemSpiderID = 3746 |
||
Revision as of 16:22, 12 September 2009
 | |
 | |
| Clinical data | |
|---|---|
| License data |
|
| Pregnancy category |
|
| Routes of administration | Oral, IV |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80% or more |
| Protein binding | 97% |
| Metabolism | Hepatic (CYP3A4- and CYP2C19-mediated) |
| Elimination half-life | 1–1.5 hours |
| Excretion | Renal and fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.173.220 |
| Chemical and physical data | |
| Formula | C16H14F3N3O2S |
| Molar mass | 369.363 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
Lansoprazole (lan-SOE-pra-zole, INN) is a proton pump inhibitor which prevents the stomach from producing acid. It is manufactured by a number of companies worldwide under several brand names (some brand names include: Prevacid, Helicid, Zoton, Inhibitol). It was first approved by the FDA in 1995.[2]
Pharmacology
Lansoprazole is a proton pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available.[3]
Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours,[4] and the effects of the drug last for over 24 hours after it has been used for 1 day or more.[citation needed]
Indications
Lansoprazole is indicated for:
- Treatment of ulcers of the stomach and duodenum, and NSAID-induced ulcers
- Treatment of gastroesophageal reflux disease (GERD) (also known as acid reflux disease)
- Treatment of Zollinger-Ellison Syndrome
- Adjunctive treatment of Helicobacter pylori infection, alongside antibiotics
Drug Interactions
- PPIs reduce absorption of antifungals (itraconazole and ketoconazole) and possibly increase Digoxin in plasma
- Increases plasma concentrations of Cilostazol (risk of toxicity)
- Absorption of lansoprazole possibly reduced by:
Side effects
- Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
- Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
- Severe: Gastro-intestinal disturbances (such as nausea 1.3%, abdominal pain 2.1%, diarrhea 3.8%).[4]
Proton pump inhibitors may be associated with a greater risk of hip fractures,[5] clostridium difficile-associated diarrhea.[6] Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.[7]
Brand names
The drug is sold under several brand names, including: [2]
- Agopton (Germany)
- Aprazol (Turkey)
- Digest (Indonesia)
- Duogast (Syria)
- Lanpro (India)
- Lanzol (India)
- Lanzul (Slovenia)
- Lansoptol (Hungary)
- Lansox (Italy)
- Lansoloc (South Africa)
- Lanton (Israel)
- Lanzor (France)
- Laprazol (Greece)
- Limpidex (Italy)
- Monolitum (Spain)
- Ogast and OgastORO (France)
- Ogastro (Mexico)
- Prevacid (U.S. and Canada) Prevacid is a product of Takeda Pharmaceuticals.
- pro-ulco (Spain)
- Prosogan and Prosogan FD (Indonesia)
- Refluxon (Hungary)
- SOLOX (New Zealand)
- Takepron (Japan)
- Zoton (Italy, Ireland, Australia, UK)
- ZOMEL (Ireland)
Lansoprazole is also available as a generic drug in the UK, Canada, Belgium, France, Colombia, Italy and Mexico.
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ a b Mosby's Drug Consult: Lansoprazole
- ^ http://www.patient.co.uk/showdoc/30002943/
- ^ a b "Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism". RxList.com. 2007. Retrieved 2007-04-14. Cite error: The named reference "RxList" was defined multiple times with different content (see the help page).
- ^ Yang YX, Lewis JD, Epstein S, Metz DC (2006). "Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture". JAMA. 296 (24): 2947–53. doi:10.1001/jama.296.24.2947. PMID 17190895.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ "Proton pump inhibitors and Clostridium difficile". Bandolier. 2003. Retrieved 2007-07-13.
- ^ Shoshana J. Herzig, MD; Michael D. Howell, MD, MPH; Long H. Ngo, PhD; Edward R. Marcantonio, MD, SM (2009). "Acid-Suppressive Medication Use and the Risk for Hospital-Acquired Pneumonia=JAMA". JAMA the Journal of the American Medical Association. 301 (20): 2120–2128. doi:10.1001/jama.2009.722. PMID 19470989.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
External links
- Prevacid (manufacturer's website)
- Prevacid Pediatrics (manufacturer's website)
- Prevpac (manufacturer's website)